Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis: M-CSF - An independent prognostic factor

Oncology

Volumn 70, Issue 2, 2006, Pages 115-125

  Kaminska, Janina ^a   Kowalska, Maria ^a   Kotowicz, Beata ^a   Fuksiewicz, Malgorzata ^a   Glogowski, Maciej ^a   Wojcik, Ewa ^b   Chechlinska, Magdalena ^a   Steifen, Jan ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Cytokines; M CSF; Non small cell lung cancer; Tumor markers

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CARCINOEMBRYONIC ANTIGEN; COLONY STIMULATING FACTOR 1; CYTOKERATIN 19 FRAGMENT; CYTOKINE; CYTOKINE RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; SOLUBLE INTERLEUKIN 2 RECEPTOR; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SERUM; SQUAMOUS CELL CARCINOMA; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKINS; KERATINS; LUNG NEOPLASMS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; ROC CURVE; SERPINS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646814418     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093002     Document Type: Article

References (52)

1. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
2. Chechlinska M: The role of cytokines in carcinogenesis. Nowotwory J Oncol 2003;6:648-659.
3. Brunetti G, Bossi A, Baiardi P, Jedrychowska I, Pozzi U, Bacchella L, Bernardo G: Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy. Lung Cancer 1999;23:1-9.
4. Brattstrom D, Bergqviest M, Hesselius P, Larsson A, Wagenius G, Brodin O: Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2004;44:55-62.
5. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J: Cytokine serum levels in soft tissue sarcoma patients: correlations with clinicopathological features and prognosis. Int J Cancer 2002;100:463-471.
6. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J: Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003;84:151-159.
7. Raziuddin S, Sheikha A, Abu-Eshy S, Al-Janadi M: Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies. Cancer 1994;73:2426-2431.
8. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G: Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000;117:365-373.
9. Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito NJ, Oramas J: Cytokine levels (IL-6 and INF-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11:80-86.
10. Kaminska J, Kowalska MM, Nowacki MP, Chwalinski MG, Rysinska A, Fuksiewicz M: CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000;6:38-41.
11. Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, Michalski W, Chechlinska M: Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble TNF RI - an independent prognostic factor. Tumor Biol 2005;26:186-194.
12. Fisher JR, Lahm H: Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer 2004;2:151-161.
13. Katsumata N, Eguchi K, Fukuda M, Yamamoto N, Ohe Y, Oshita F, Tamura T, Shinkai T, Saijo N: Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 1996;2:553-559.
14. Fontanini G, Vignati S, Lucchi M, Mussi A, Calcinai A, Boldrini L, Chine S, Silvestri V, Angeletti CA, Basolo F, Bevilacqua G: Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997;75:1295-1301.
15. Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T: Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol 1998;28:740-744.
16. Orditura M, De Vita F, Catalano G, Infusino S, Lieto E, Martinelli E, Morgillo F, Castellano P, Pignatelli C, Galizia G: Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 2002;22:1129-1135.
17. Songur N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H, Hizel N: Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004;90:196-200.
18. Wu J, Saldana L, Chillar R, Vadgama JV: Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol 2002;20:509-516.
19. Mroczko B, Szmitkowski M, Wereszczyńska-Siemia̧tkowska U, Jurkowska G: Hematopoietic cytokines in the sera of patients with pancreatic cancer. Clin Chem Lab Med 2005;43:146-150.
20. Mroczko B, Szmitkowski M, Wereszczyńska-Siemia̧tkowska U, Okulczyk B: Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer. Dig Dis Sci 2005;50:1019-1024.
21. Wiik H, Karttunen R, Haukipuro K, Syrjala H: Maximal local and minimal systemic cytokine response to colorectal surgery: the influence of perioperative filgrastim. Cytokine 2001;14:188-192.
22. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, van de Water L: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992;176:1375-1379.
23. Sugawara T, Gallucci RM, Simeonova PP, Luster MJ: Regulation and role of interleukin 6 in wounded human epithelial keratinocytes. Cytokine 2001;15:328-336.
24. Tisi E, Lissoni P, Angeli M, Arrigoni C, Corno E, Cassina E, Ballabio D, Benenti C, Barni S, Tancini G: Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer 1992;69:2458-2462.
25. Dinarello CA, Wolf T SM: The role of interleukin-1 in disease. N Engl J Med 1993;328:106-113.
26. Osman O, Gesser B, Mortensen JT, Matsushima K, Jensen SL, Larsen CG: Profiles of proinflammatory cytokines in the serum of rabbits after experimentally induced acute pancreatitis. Cytokine 2002;17:53-59.
27. Atwell DM, Grichnik KP, Newman MF, Reves JG, McBride WT: Balance of proinflammatory and anti-inflammatory cytokines at thoracic cancer operation. Ann Thorac Surg 1998;66:1145-1150.
28. Shacter E, Weitzman SA: Chronic inflammation and cancer (review). Oncology (Williston Park) 2002;16:217-226, 229;discussion 230-232.
29. Dvorak HF: Tumors: wounds that do not heal. N Engl J Med 1986;315:1650-1659.
30. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
31. Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ: The effect of surgical wounding on tumour development. Eur J Surg Oncol 1999;25:231-243.
32. Nowacki MP, Janik P, Nowacki PM: Inflammation and metastases. Med Hypotheses 1996;47:193-196.
33. De Vita F, Orditura M, Auriemna A, Infusino S, Catalano G: Serum concentrations of proinflammatory cytokines in advanced non-small cell lung cancer patients. J Exp Clin Cancer Res 1998;17:413-417.
34. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G: Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998;5:649-652.
35. Suzuki M, Ohwada M, Sato I, Nagamoto M: Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Oncology 1995;52:128-133.
36. McDermott RS, Deneux L, Mosseri V, Vedrenne J, Clough K, Fourquet A, Rodriguez J, Cosset JM, Sastre X, Beuzeboc P, Pouillart P, Scholl SM: Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw 2002;13:121-127.
37. Yee LD, Liu L: The constitutive production of colony stimulating factor 1 by invasive human breast cancer cells. Anticancer Res 2000;20:4379-4383.
38. Kacinski BM, Carter D, Mittal K, Yee LD, Scata KA, Donofrio L, Chambers SK, Wang KI, Yang-Feng T, Rohrschneider LR: Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 1990;137:135-147.
39. Kacinski BM: CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995;27:79-85.
40. Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N: Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer 1999;79:40-46.
41. Filderman AE, Bruckner A, Kacinski BM, Deng N, Remold HG: Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines. Cancer Res 1992;52:3661-3666.
42. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillart P, Lidereau R: Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994;86:120-126.
43. Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-739.
44. Chambers SK, Wang Y, Gertz RE, Kacinski BM: Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 1995;55:1578-1585.
45. Nowicki A, Szenajch J, Ostrowska G, Wojtowicz A, Wojtowicz K, Kruszewski AA, Maruszynski M, Aukerman SL, Wiktor-Jedrzejczak W: Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer 1996;65:112-119.
46. Fujiwaki R, Iida K, Nakayama K, Kanasaki H, Hata K, Katabuchi H, Okamura H, Miyazaki K: Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecol Oncol 2002;89:77-83.
47. Trape J, Buxo J, Perez de Olaguer J: Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer. Clin Chem 2003;49:523-525.
48. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK: Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small cell lung cancer. Ann Oncol 2002;13:1550-1557.
49. Brattstrom D, Bergqvist M, Larsson A, Holmertz P, Hesselius P, Rosenberg L, Brodin O, Wagenius G: Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998;18:1123-1127.
50. Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L, Khuri FR: Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2003;9:1758-1791.
51. Ikonomidis I, Lekakis J, Vamvakou G, Andreotti F, Nihoyannopoulos P: Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J 2005;149:832-839.
52. Jelkmann W: Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001;47:617-623.